Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 372Neoplasms 263Prostatic Neoplasms 188Lung Neoplasms 137Colorectal Neoplasms 128Head and Neck Neoplasms 76Colonic Neoplasms 67Pancreatic Neoplasms 63Carcinoma, Non-Small-Cell Lung 63Carcinoma, Hepatocellular 61Uterine Cervical Neoplasms 57Multiple Myeloma 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 53Neoplasm Metastasis 51Leukemia, Myeloid, Acute 50Brain Neoplasms 48Liver Neoplasms 44Rectal Neoplasms 42Melanoma 42Motor Activity 41Lymphoma, Non-Hodgkin 41Lymphoma 39Leukemia 38Pain 37Ovarian Neoplasms 36Hodgkin Disease 36Fatigue 34Depression 34Barrett Esophagus 34Lymphoma, Follicular 33

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Has results × Hypereosinophilic Syndrome × Clear all
NCT00038675 2022-01-04

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

M.D. Anderson Cancer Center

Phase NA Completed
125 enrolled 9 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Polycythemia Vera, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡